ONWARD Announces Participation at Upcoming Events
EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA, Jan. 16, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced that management will participate in the following events in the upcoming weeks:
- Degroof Petercam Healthcare Conference
January 26, 2023
Dave Marver, CEO, will participate in 1:1 meetings.
- TechShare by Euronext
January 27, 2023
Dave Marver will deliver the keynote address at the annual IPO educational program organized by Euronext.
- Sachs 4th Annual European HealthTech CEO Forum
February 28, 2023
Dave Marver will participate in the panel discussion, “NextGen Medtech & Devices”.
- BioCapital Europe
March 9, 2023
Dave Marver will give a company presentation.
- Oppenheimer 33rd Annual Healthcare Conference
March 13-15, 2023
Dave Marver or Lara Smith Weber, CFO, will give a company presentation.
- VFB Happening (Flemish Federation of Investors)
March 25, 2023
Dave Marver will give a company presentation.
Information on upcoming conferences is available in the Investor section of the ONWARD website at https://ir.onwd.com/news-events.
About ONWARD Medical
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.
ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.
ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com. To access our 2023 Financial Calendar, please visit IR.ONWD.com.
For Investor Enquiries:
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Upcoming Life Sciences Events
- February 2023
- Biotechgate Digital Partnering February 2023
- Dusseldorf: 7th ECP - The first industry speed dating event
- March 2023
- Zurich: 16th Annual European Life Sciences CEO Forum